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Background: While chronic renal damage is a condition with low-grade inflammation, the potential role of
inflammation in kidney disease as a marker of cardiovascular damage is of current interest. This study analyzed the
relationship between renal dysfunction, chronic inflammation, and extension of coronary atherosclerosis in patients
with non-ST-segment elevation myocardial infarction (NSTEMI).
Methods: This retrospective study was carried out on consecutive patients presenting with NSTEMI to Maggiore
Hospital’s emergency department between January 1, 2010 and December 31, 2011. Patients’ electronic charts were
reviewed to gather information on patients’ history, clinical and biochemical variables, with a special focus on
inflammatory markers, coronary vessel damage, and drug treatments.
Results: Of the 320 individuals in the study population, 138 (43.1%) had an admission GFR <60 mL/min/1.73 m2.
Kidney dysfunction was significantly associated with age (OR = 1.09, 95% CI 1.06 to 1.12), history of heart failure
(OR = 2.13, 95% CI 1.08 to 4.17), and hypertension (OR = 2.31, 95% 1.12 to 4.74). C-reactive protein (CRP) and uric
acid levels were significantly increased in patients with severe renal dysfunction (SRD) by bivariate and multivariate
analyses, adjusted for gender, age and comorbidities at admission. The extent of coronary artery disease (CAD) was
significantly higher in the SRD group (p < 0.001). Individuals with SRD were less likely to receive immediate
evidence-based therapies (62.9% vs. 76.7% and 82.0% in those with intermediate and no/mild renal dysfunction,
p < 0.001). Hospital stay was significantly longer in individuals with a greater extent of CAD, diabetes, and a history
of heart failure, and was borderline significantly associated with renal dysfunction (p = 0.08). Older age, CAD
severity, and renal function were associated with worsening GFR during hospitalization, whereas immediate
evidence-based treatment was unrelated to a GFR change.
Conclusions: Among individuals hospitalized for NSTEMI, those with SRD had a more extensive CAD and a higher
prevalence of pre-existing cardiovascular disease. CRP was positively correlated with renal dysfunction and the
number of involved coronary vessels, confirming its potential as a biomarker. Uric acid was associated with renal
dysfunction but not with the number of diseased coronary vessels.* Correspondence: gaetano.lamanna@unibo.it
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Chronic kidney disease (CKD) is a worldwide public health
problem, which is becoming increasingly relevant as life
expectancy of the world’s population has increased. Pa-
tients with CKD have an increased risk of end-stage renal
failure and cardiovascular disease (CVD). There is a
graded and independent correlation between the glomeru-
lar filtration rate (GFR) and CVD outcomes [1].
CKD is characterized by the presence of systemic,
low-grade inflammation, and researchers have recently
focused on the role of inflammatory markers as links
between cardiovascular and kidney disease [2,3]. The
principal aim of this study was to analyze the relation-
ship between renal function at admission, coronary ar-
tery disease (CAD) severity, and inflammation markers
in patients hospitalized for non-ST-segment elevation
myocardial infarction (NSTEMI). The secondary aims
were to evaluate the in-hospital outcomes and 1-year
and 2-year mortality rates of these patients.
Methods
Study population
The study included consecutive patients presenting to the
Emergency Department of Maggiore Hospital from Janu-
ary 1, 2010 to December 31, 2011, with a NSTEMI.
NSTEMI diagnosis was based on electrocardiographic
(ECG) ST-segment depression or prominent T-wave in-
version and/or positive biomarkers of necrosis (e.g., tropo-
nin) in the absence of ST-segment elevation and in an
appropriate clinical setting (chest discomfort or anginal
equivalent) as defined in American College of Cardiology/
American Heart Association guidelines [4]. The diagnostic
cut-off for myocardial infarction was defined as a cardiac
troponin measurement exceeding the 99th percentile of a
normal reference population (upper reference limit) using
an assay with an imprecision (coefficient of variation) of ≤
10% at the upper reference limit. Our Laboratory uses the
SIEMENS Dimension EXL TM integrated chemistry sys-
tem. The reference interval for Troponin I was 0.000-
0.056 ng/mL. [5,6].” According to the ACC/AHA and ESC
guidelines for NSTEMI management, an early invasive
strategy (diagnostic angiography with intent to perform re-
vascularization) is indicated in initially stabilized NSTEMI
patients (without serious comorbidities or contraindica-
tions to such procedures) who have an elevated risk for
clinical events. For patients not at high risk, a delayed
invasive approach is also reasonable. The study was
approved by the ethics committee of the S.Orsola
University Hospital of Bologna. Data were extracted from
the patients’ electronic medical records and all patient-
identifying information was removed before analysis,
in compliance with the Italian privacy law (Act No. 67,
December 31, 1996). Patients with severe infections (sep-
sis, lung infections, and urinary sepsis) were excluded. Nolower limit for the value of GFR was used as an exclusion
criterion.
The patients were classified into three groups: no/mild
renal dysfunction (≥60 mL/min/1.73 m2 intermediate
renal dysfunction (31–59 mL/min/1.73 m2), and severe
renal dysfunction (<30 mL/min/1.73 m2) according to
their renal function at admission (aGFR). aGFR was esti-
mated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula, to characterize serum
creatinine levels in relation to age and gender.
CAD was assessed in those patients who underwent cor-
onary angiography. CAD severity was defined as the num-
ber of vessels with ≥1 obstructive atherosclerotic lesions,
defined as lesions producing ≥50% reduction in diameter
of the left main coronary artery or ≥70% reduction in
diameter of the major epicardial vessels. Immediate
evidence-based treatment was defined as the use of as-
pirin, clopidogrel, low-molecular-weight-heparin (LMWH),
beta-blockers, angiotensin converting enzyme (ACE) in-
hibitors, and statins. Mortality rates at 1 and 2 years after
discharge were obtained by linking patient data with the
Sistema Informativo Politiche per la Salute e Politiche
Sociali (SISEPS) database of Emilia-Romagna region.Statistical analysis
Continuous variables were compared using analysis of
variance (ANOVA) F, Kruskal-Wallis, or median tests,
followed by post-hoc pairwise tests. Categorical variables
were compared using the χ2 test. Bonferroni correction
was applied to the probability level to control for pos-
sible type-I error. Multiple logistic regression was used
to predict aGFR as a function of gender, age and comor-
bidities at admission. Multiple linear regression analysis
was used to predict the number of vessels with CAD, C-
reactive protein (CRP) levels, and troponin levels as a
function of aGFR, gender, age, and comorbidities at
admission. The change in GFR from admission to
discharge was analyzed as a function of renal function,
comorbidities, severity of CAD, age, gender, and left
ventricular dysfunction (defined as ejection fraction
[EF] ≤40%) at admission, using multiple linear regression.
The GFR change was determined by subtracting aGFR
from the discharge GFR. Therefore, a positive change indi-
cates improvement from baseline and a negative change
indicates worsening. Patients undergoing dialysis were ex-
cluded from the GFR change analysis.
Multiple linear regression analysis was also used to
evaluate the relationship between the length of hospital
stay and renal function, comorbidities, CAD severity,
age, gender, and left ventricular dysfunction at admis-
sion. Length of hospital stay was normalized by square
root transformation. All analyses were performed using
SPSS, version 20.0.
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Patient admission characteristics
During the study period, 334 patients presented with
NSTEMI. Fourteen were excluded from analysis: one for
generalized sepsis, nine for lung infections, and four for
urinary sepsis. The study population included 320 pa-
tients: 182 had no/mild, 103 had intermediate, and 35
had severe renal dysfunction. Among these 35 patients,
10 were CKD stage 5D patients on chronic hemodialysis
treatment .Compared with patients with no/mild dys-
function, those with intermediate or severe dysfunction
were significantly older and more likely to be female and
have left ventricular dysfunction and a history of heart
failure, diabetes, hypertension, peripheral artery disease,
or previous MI (Table 1).
Patients with mild and moderate renal dysfunction
had a significantly higher diastolic arterial pressure
(DAP) and mean arterial pressure (MAP) than patients
with severe renal dysfunction (DAP: 80 ± 12 mm Hg




Age, mean (SD) (years) 68.7 (12.5)
Female, n (%) 49 (26.9)
History of lipid disorder, n (%) 106 (58.2)
History of diabetes, n (%) 45 (24.9)
History of hypertension, n (%) 130 (71.8)
History of PAD, n (%) 11 (6.1)
Prior myocardial infarction, n (%) 68 (37.6)
Prior stroke or TIA, n (%) 16 (8.8)
Left ventricular dysfunction (EF≤ 40), n (%) 26 (14.3)
History of heart failure, n (%) 24 (13.2)
Renal function characteristics
GFR at admission, mean (SD) (mL/min/1.73 m2 ) 81.1 (13.6)
GFR at peak, mean (SD) (mL/min/1.73 m2 ) 73.7 (16.4)
GFR at discharge, mean (SD) (mL/min/1.73 m2 ) 80.9 (15.8)





ACE inhibitors 163 (91.1)
Statins 152 (84.4)
Immediate evidence-based treatment, n (%) 162 (89.0)
*Bonferroni-corrected p value was used for Post-hoc analysis.
Abbreviations: GFR glomerular filtration rate, SD standard deviation, PAD peripheral
low-molecular-weight-heparin, ACE angiotensin-converting enzyme.ANOVA F = 6.3, p = 0.002; MAP: 100 ± 17 mm Hg and
100 ± 14 mm Hg vs. 92 ± 17 mm Hg, respectively, ANOVA
F = 4.1, p = 0.018). Systolic blood pressure did not differ
significantly among the three aGFR groups (ANOVA F =
1.781, p = 0.0170).
During multiple logistic regression including age, gen-
der, and comorbidities at admission, kidney dysfunction
was significantly associated with age (odds ratio [OR] =
1.09, 95% confidence interval [CI] = 1.06 to 1.12), heart
failure history (OR = 2.13, 95% CI = 1.08 to 4.17), and
hypertension (OR = 2.31, 95% CI = 1.12 to 4.74).
Regarding evidence-based drug treatment, patients with
severe renal dysfunction were less likely to receive ACE in-
hibitors, statins, and aspirin than patients with no/mild dys-
function; those with intermediate renal dysfunction were
less likely to receive beta-blockers and LMWH (Table 1).
Overall, a majority of patients with no/mild and inter-
mediate renal dysfunction received immediate evidence-
based treatment, but only 62.9% of those with severe
renal dysfunction received this treatment.the study sample by level of kidney function
Group B: Group C: P-value Post-hoc
GFR 59-30 GFR <30 Significant
(n = 103) (n = 35) Comparisons*
81.2 (8.8) 79.5 (11.0) <.0001 A < B,C
46 (44.7) 23 (65.7) <.0001 A < B < C
59 (57.3) 15 (42.9) 0.236 -
37 (35.9) 18 (51.4) 0.004 A < B,C
87 (84.5) 29 (82.9) 0.035 A < B
14 (13.6) 7 (20.0) 0.015 A < B,C
49 (48.0) 24 (70.6) 0.001 A,B < C
17 (16.5) 7 (20.0) 0.061 -
27 (26.2) 11 (31.4) 0.011 A < B,C
38 (36.9) 14 (40.0) <.0001 A < B,C
45.5 (8.8) 18.1 (7.7) <.0001 A > B > C
41.8 (10.1) 16.0 (9.3) <.0001 A > B > C
51.4 (15.4) 22.9 (16.9) <.0001 A > B > C
99 (96.1) 27 (77.1) <.0001 A,B > C
97 (94.2) 31 (88.6) 0.513 -
95 (92.2) 33 (94.3) 0.037 A > B
93 (90.3) 32 (91.4) 0.036 A > B
91 (88.3) 22 (62.9) <.0001 A,B > C
79 (77.5) 19 (54.3) <.0001 A,B > C
79 (76.7) 22 (62.9) <.0001 A > B,C
arterial disease, TIA transient ischemic attack, EF ejection fraction; LMWH
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and renal dysfunction
Three-vessel lesions were more common in patients with
severe (83.3%) and intermediate (50%) renal dysfunction
than in patients with no/mild dysfunction (32.3%) (Table 2).
CRP and uric acid (UA) were significantly higher in pa-
tients with severe renal dysfunction (Table 2). Distinguish-
ing ESRD patients on dialysis treatment and patients with
GFR < 30 ml/min/1.73m2 on conservative therapy, we
compared the groups in terms of inflammatory markers:
differences previously identified remained significant (CRP
median [IQR]: 1.3 (0.48-5.50) vs 2.9 (1.14-10.89). When the
relationships between inflammatory markers and renal dys-
function (as a continuous variable) were analyzed using
multiple linear regression and adjusted for comorbidities,
age, and gender, CRP and UA remained significantly associ-
ated with the degree of renal dysfunction.
Figure 1 shows the relationship between troponin I, CRP,
UA, renal dysfunction severity, and number of vessels with
lesions in the 249 patients who underwent coronary angi-
ography. Only CRP was significantly associated with CKD
severity in patients with three-vessel CAD. CRP levels were
significantly higher in patients with three-vessel lesions
than in those without three-vessel lesions (CRP mean ±
standard deviation [SD]: 1.07 ± 2.26 vs. 1.79 ± 2.75, p =
0.03). UA levels were significantly higher in patients with
severe and intermediate renal dysfunction compared to
those with no/mild renal dysfunction (Table 2), but
were unrelated to the number of vessels involved (UA
mean ± SD (3vessels CAD vs. <3vessels CAD): 6.46 ±
2.07 vs. 6.79 ± 1.81, p = 0.204).
In-hospital renal and other outcomes
The length of hospital stay increased linearly with the level
of renal dysfunction, from a mean of 5.6 days to 8.2 days
(Table 3). During multiple linear regression analysis of theTable 2 Relationship between myocardial damage, inflammat
kidney function
Variables Group A: Group
GFR ≥60 GFR 59
(n = 182) (n = 10
In hospital markers
Troponin I, median (IQR), ng/mL 1.2 (0.33-6.46) 2.3 (0.48-
CRP, median (IQR), mg/mL 0.3 (0.17-1-13) 0.69 (0.23
Uric acid, median (IQR), mg/mL 5.9 (4.95-7.2) 7.5 (6.1-
Angiographic findings, n (%)†
No CAD 14/167 (8.3) 4/70 (5
1- and 2-vessel CAD 99/167 (59.3) 31/70 (4
3-vessel CAD 54/167 (32.3) 35/70 (5
*Bonferroni-corrected p value was used for Post-hoc analysis.
Abbreviations: GFR glomerular filtration rate, IQR interquartile range, CRP cross-react
† In the 249 patients who underwent coronary angiography.249 patients with angiography results, the length of hos-
pital stay was significantly associated with the extent of
CAD, presence of diabetes, and history of heart failure,
and borderline significantly associated with renal dysfunc-
tion (p = 0.08) (Table 4).
The mean GFR of all patients (excluding the 10 receiving
dialysis) improved from admission to discharge by 2.3 mL/
min/1.73 m2 (SD = 12.5). The percentage change in GFR
was 0.4%, 13.2%, and 32.3% in patients with no/mild, mod-
erate, and severe admission renal dysfunction, respectively.
Older age, CAD severity, and renal function were associ-
ated with worsening GFR during hospitalization, whereas
immediate evidence-based treatment was unrelated to a
change in GFR (Table 5).
In-hospital mortality was low, with only six deaths
(1.8%) total (Table 1). Patients who died during the
hospitalization had variable admission renal function: their
aGFR ranged from 20.9 to 79.6 mL/min/1.73 m2. Among
the 317 patients with a positive link to the SISEPS register,
the 1–year mortality rate was 15.3% and the 2-year mor-
tality rate was 21.3%.Discussion
Our results indicate that 43.1% of patients hospitalized for
NSTEMI had renal dysfunction at admission. This per-
centage is considerably higher than in the general popula-
tion, confirming the relationship between CVD and renal
dysfunction [7-10]. CAD was more severe in patients with
more severe kidney damage, and the number of patients
with three-vessel CAD increased with increasing renal
dysfunction. Our study showed this relationship, which
had previously been reported only for registry studies [11].
We also found that CRP increased with increasing renal
dysfunction and that its levels were associated with the ex-
tent of CAD, suggesting that this proteinas inflammationion, and severity of coronary artery disease by level of
B: Group C: P value Post-hoc
-30 GFR <30 Significant
3) (n = 35) Comparisons*
6.51) 2.9 (0.61-6.27) 0.052 A < C
-2.65) 1.9 (0.73-7.67) <0.001 A,B < C
9.4) 7.2 (5.8-8.3) <0.001 A < B,C
0.002
.7) 0 -
4.3) 2/12 (16.7) A > C
0) 10/12 (83.3) A < B,C
ive protein, CAD coronary artery disease.
Figure 1 Median levels of inflammatory markers as a function
of renal dysfunction and number of coronary vessels involved.
Abbreviations: CRP, C-reactive protein.
Table 3 In-hospital outcomes
Variables Group A: Gro
GFR ≥60 GFR
(n = 182) (n =
In hospital outcomes
Length of hospital stay, mean (SD) (days) 5.6 (4.9) 7.9
In-hospital death, n (%) 3 (1.6) 1
*Bonferroni-corrected p value was used for Post-hoc analysis.
Abbreviations: SD standard deviation.
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CAD.
Recent research has focused on the role of inflammatory
markers as a link between CVD and kidney disease. CKD
is characterized by chronic inflammation, and inflamma-
tion also plays an integral role in accelerated atheroscler-
osis. Systemic microinflammation determines the extent
of vascular endothelium damage, which is a key risk factor
for both acute coronary syndrome (ACS) and CKD pro-
gression [12,13]. Patients with ACS and increased CRP
have a worse outcome than those with normal levels of in-
flammatory markers [14]. Moreover, CRP is an important
predictor of ACS. Inflammatory activation may also play a
role in heart failure by contributing to vascular dysfunc-
tion and fluid overload [15], thereby leading to inadequate
renal perfusion pressure, peritubular edema, pathological
reduction of glomerular filtration, and mixed inflamma-
tory and ischemic tubular damage [16]. These effects may
explain why heart failure on admission was more frequent
in our patients with CKD and was directly related to the
extent of renal damage. Our finding of an association be-
tween UA levels and renal dysfunction is consistent with
previously reported associations between UA and obesity,
hypertension, metabolic syndrome, and glucose intoler-
ance, all of which contribute to the pathogenesis of CVD
[17,18]. Although some epidemiological, experimental,
and clinical data have implicated UA in the pathogenesis
of kidney injury [19], other studies have not demonstrated
a clear effect of UA in the pathogenesis of endothelial
damage [20]. Conversely, UA levels were unrelated to the
number of diseased coronary arteries. These results sug-
gest that increased UA may be the consequence of various
factors, such as reduced urinary excretion due to renal
dysfunction, cardiac disease, hypertension, or metabolic
syndrome [21]. Alternately, they might be involved in the
early phases of vascular damage [22].
Our observation that patients with renal dysfunction at
admission were older than those without renal dysfunction
is consistent with previous findings [23]. Furthermore, older
patients had worsening of their GFR during hospitalization.
Patients with severe admission renal dysfunction had a
lower diastolic and mean arterial pressure, which concurs
with a recent report that diastolic hypotension is moreup B: Group C: P value Post-hoc
59-30 GFR <30 Significant
103) (n = 35) Comparisons*
-
(6.3) 8.2 (4.8) 0.001 A < B < C
(1.0) 2 (5.7) 0.193 -
Table 4 Predictors of length of hospital stay: multiple linear regression analysis results
Independent variables b P value 95% Confidence interval
Gender (male) 0.02 0.87 −0.173 to 0.204
Age (years) 0.00 0.74 −0.007 to 0.009
Immediate evidence-based treatment −0.19 0.18 −0.464 to −0.090
GFR at admission (mL/min/1.73 m2 ) 0.00 0.08 −0.008 to −0.001
Number of vessels with CAD 0.12 0.01 0.029 to 0.217
Left ventricular dysfunction (EF ≤40) 0.11 0.38 −0.133 to 0.349
History of heart failure 0.45 <0.001 0.211 to 0.681
History of PAD 0.12 0.44 −0.184 to 0.420
History of diabetes 0.26 0.01 0.072 to 0.446
History of lipid disorders −0.13 0.13 −0.307 to 0.040
History of hypertension 0.00 0.99 −0.196 to 0.194
Prior myocardial infarction −0.12 0.20 −0.299 to 0.064
Prior stroke or TIA 0.16 0.27 −0.123 to 0.445
Abbreviations: GFR glomerular filtration rate, CAD coronary artery disease, EF ejection fraction, PAD peripheral arterial disease, TIA transient ischemic attack.
Values in bold are statistically significant.
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observations may be partially explained by age-related
decreases in GFR, due to reduced arterial compliance,
changes in afterload, and diastolic dysfunction [25,26].
Moreover, excluding from the study population pa-
tients in chronic dialysis, patients with severe renal dys-
function at admission also presented a more substantial
improvement in GFR at discharge: these data may re-
flect the effect on renal function of the patient’s clinical
condition stabilization. Other events may also have con-
tributed, such as the discontinuation of ACE inhibitors,





Immediate evidence based treatment −0.84
GFR at admission (mL/min/1.73 m2 ) −0.34
History of heart failure −2.60
History of PAD 4.04
History of diabetes 1.00
History of lipid disorders −2.15
History of hypertension 0.48
Prior myocardial infarction −0.36
Prior stroke or TIA −2.38
Number of vessels with CAD 1.77
Ejection fraction (≤40) −3.29
Dialysis patients (n = 10) where excluded from the analysis.
Values in bold are statistically significant.
Abbreviations: GFR glomerular filtration rate, CAD coronary artery disease, EF ejectiodid not analyze patients’ medications before hospital
admission but during the first 24 hours. In these
period, ACE inhibitors were administered to all pa-
tients in the absence of the contraindications (hyperka-
liemia, hypotension), independently of the presence or
absence of renal dysfunction.
Our data confirm the use of evidence-based therapy in
a high percentage of patients with NSTEMI and a care-
ful use of multiple drugs in patients with severe renal
dysfunction. Interestingly, use of clopidogrel did not dif-
fer among the study groups, but patients with severe
renal dysfunction were less likely to receive immediateadmission to discharge: multiple linear regression
P value CI 95%
0.26 −1.418 to 5.262
<0.001 −0.549 to −0.243
0.74 −5.803 to 4.116
<0.001 −0.423 to 0.253
0.21 −6.704 to 1.513
0.16 −1.589 to 9.663
0.55 −2.309 to 4.307
0.17 −5.212 to 0.915
0.78 −2.908 to 3.862
0.83 −3.544 to 2.833
0.35 −7.436 to 2.675
0.03 0.138 to 3.407
0.13 −7.497 to 0.924
n fraction, PAD peripheral arterial disease, TIA transient ischemic attack.
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mission. Patients with renal dysfunction had a longer
hospitalization, although this association became weaker
after adjusting for gender, age, immediate treatment, and
comorbidities. Our in-hospital mortality rate was low
(1.8%), which may reflect the quality of care received and/
or exclusion of patients with severe infection. Our small
number of deaths prohibited determining whether mortal-
ity was associated with aGFR or immediate evidence-based
treatment, as suggested by other authors [27-30]. Never-
theless, 1-year and 2-year mortality rates were 15.3% and
21.3%, confirming NSTEMI as a life-threatening condition.
The study is limited by its retrospective-observational
nature and the relatively small sample size. Data regard-
ing renal function before admission was frequently not
available in the patients’ charts.
Thus, we cannot confirm that the aGFR values represent
the patients’ baseline value. Nevertheless, because the time
from NSTEMI onset to admission was minimal and cre-
atinine is a late marker of renal function changes, aGFR
probably at least reflected the renal function associated
with the hemodynamic changes related to NSTEMI.
Moreover, only a single CRP value was available for all
patients.Conclusions
Our results indicate that, among patients hospitalized
for NSTEMI, those with a severe degree of renal dys-
function had more diffuse CAD. CRP was also positively
correlated with renal dysfunction, confirming its possible
use as a biomarker of the extent of coronary atheroscler-
osis in patients with CKD. The role of UA is unclear, as
there was no association between UA and the number of
diseased coronary arteries.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
MU: design of the study, data collection, revision of the draft paper; GG and
GDP: design of the study, revision of the draft paper; AM: analysis of the data,
writing of the draft paper and revision of the draft paper; FR: data collection,
revision of the daft paper; VD: study design, revision of the draft paper; IC:
writing of the draft and revision of the paper; LS: data collection and revision of
the draft paper; GC: study design and revision of the draft of the paper; PR:
writing of the statistical analysis, planning and analysis of the data, and revision
of the draft paper; GLM: study design, analysis of the data, and revision of the
draft paper. All authors read and approved the final manuscript.
Author details
1Emergency Department, Maggiore Hospital, Bologna, Italy. 2Cardiology
Department, Maggiore Hospital, Bologna, Italy. 3Department of Biomedical
and Neuromotor Sciences, Section of Public Health, University of Bologna,
Bologna, Italy. 4Dialysis Unit, Maggiore Hospital, Bologna, Italy. 5Department
of Experimental, Diagnostic and Specialty Medicine, Nephrology Dialysis and
Transplantation Unit, S. Orsola Hospital, University of Bologna, Bologna, Italy.
Received: 3 April 2014 Accepted: 10 September 2014
Published: 17 September 2014References
1. Shani S, Sarnak MJ: Cardiovascular disease and CKD: Core Curriculum
2010. Am J Kidney Dis 2010, 56(2):399–417.
2. Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from
pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129–2138.
3. Hansson KK: Inflammation. Atherosclerosis and coronary artery disease.
N Engl J Med 2005, 352:1685–1695.
4. Anderson JL, Adams CD, Antman EM, Bridges CR, Callif RM, Casey DE,
Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED,
Theroux P, Wenger NK, Wright RS: ACC/AHA Focused update incorporated
into the ACC/AHA 2007 guidelines for the management of patients with
unstable Angina/Non-ST-elevation myocardial infarction: a report of the
American college of cardiology foundation/American heart association
task force on practice guidelines. Circulation 2012, 2013:127.
5. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P,
Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Sousa Uva M,
Storey RF, Wijns W, Zahger D: ESC Guidelines for the management of
acute coronary syndromes in patients presenting without persistent
ST-segment elevation. The Task Force for the management of acute
coronary syndromes (ACS) in patients presenting without persistent
ST-segment elevation of the European Society of Cardiology (ESC).
Eur Heart J 2011, 32:2999–3054.
6. The SIEMENS Dimension EXL TM integrated chemistry system. LOCI
Module. Issue Date 2012-11-13. http://www.healthcare.siemens.com/
integrated-chemistry/systems/dimension-exl-200-integrated-chemsys/assays.
7. Centers for Disease Control and Prevention: National Chronic Kidney Disease
Fact Sheet: General Information and National Estimates on Chronic Kidney
Disease in the United States. 2010. Atlanta GA: U.S. Department of Health and
Human Services. CDC; 2010.
8. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo
JF, Kontos MC, Wiviott SD: Use of evidence –based therapies in short
term out comes of ST-segment elevation myocardial infarction and
non- ST-segment elevation myocardial infarction in patients with chronic
kidney disease: A report from the national cardiovascular data acute
coronary treatment and intervention outcomes network registry.
Circulation 2010, 121:357–365.
9. Han JH, Chandra A, Mulgund J, Roe MT, Peterson ED, Szczech LA, Patel U, Ohman
EM, Lindsell CJ, Gibler WB: Chronic kidney disease in patients with Non-
STsegment elevation acute coronary syndromes. Am J Med 2006, 119:248–254.
10. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, Frederick
PD, Every N: Temporal trends in the treatment of over 1.5 million patients with
myocardial infarction in the US from 1990 through 1999: the National Registry
of Myocardial Infarction 1. 2 and 3. J Am Coll Cardiol 2000, 36:2056–2063.
11. Hanna EB, Chen AY, Roe MT, Sausedo JF: Characteristics and in-hospital
outcomes of patients presenting with non ST-segment elevation
myocardial infarction found to have significant coronary artery disease
on coronary angiography and managed medically: stratification
according to renal function. Am Heart J 2012, 164:52–55.
12. Crea F, Liuzzo G: Pathogenesis of acute coronary syndromes. J Am Coll
Cardiol 2013, 1161:1–11.
13. Rosner MH, Ronco C, Okusa MD: The role of inflammation in the
cardio-renal syndrome: a focus on cytokines and inflammatory
mediators. Semin Nephrol 2012, 32:70–78.
14. Kaski JC: C-reactive protein improves risk prediction in patients with
acute coronary syndrome. or does it? Eur Heart J 2010, 31:274–277.
15. McCullough PA, Omland T, Maisel AS: B-type natriuretic peptides: a
diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003, 4:72–80.
16. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1
pathophysiological crosstalk leading to combined heart and kidney
dysfunction in the setting of acutely decompensated heart failure.
J Am Coll Cardiol 2012, 60:1031–1042.
17. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI,
Elisaf MS: Effects of statin treatment on uric acid homeostasis in patients
with primary hyperlipidemia. Am Heart J 2004, 148:635–640.
18. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M: Uric acid metabolism
and tubular sodium handling. Results from a population-based study.
JAMA 1993, 270:354–359.
19. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, Tabah-Fisch I,
Keller B, Beaver TM, Nakagawa T, Johnson RJ: Could uric acid have a role
in acute renal failure? Clin J Am Soc Nephrol 2007, 2(1):16–21. Epub 2006
Dec 6.
Udeanu et al. BMC Nephrology 2014, 15:152 Page 8 of 8
http://www.biomedcentral.com/1471-2369/15/15220. Culleton BF, Larson MG, Kannel WB: Serum uric acid and risk for
cardiovascular disease and death: the Framingham heart study.
Ann Intern Med 1999, 131(1):7–13.
21. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular disease. N Engl
J Med 2008, 359(17):1811–1821.
22. Mazzali M, Hughes J, Kim YG: Elevated uric acid increases blood pressure
in the rat by a novel crystal-indipendent mechanism. Hypertension 2001,
38(5):1101–1106.
23. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Piñero G, Avezum A, Gulba D,
Esteban J, Gore JM, Johnson J, Gurfinkel EP, GRACE Investigators: Creatinine
clearance and adverse hospital outcomes in patients with acute
coronary syndromes: findings from the global registry of acute coronary
events (GRACE). Heart 2003, 89(9):1003–1008.
24. Tomlinson LA, Holt SG, Leslie AR, Rajkumar C: Prevalence of ambulatory
hypotension in elderly patients with CKD stage 3 and 4. Nephrol Dial
Transplant 2009, 24(12):3751–3755.
25. Lakatta E, Gerstenblith G, Weisfeldt M: The Aging Heart: Structure.
Function and Disease. In Heart Disease. Edited by Braunwald E. Philadelphia
Pa: WB Saunders; 1997:1687–1703.
26. Douville P, Martel A, Talbot J, Desmeules S, Langlois S, Agharazii M: Impact
of age on glomerular filtration estimates. Nephrol Dial Transplant 2009,
24:97–103.
27. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD,
Giugliano RP, Cannon CP, Antman EM, Braunwald E, TIMI Study Group:
Association of glomerular filtration rate on presentation with
subsequent mortality in non-ST-segment elevation acute coronary
syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J
2004, 25(22):1998–2005.
28. Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ: Renal function and
long term mortality after unstable angina/non-ST segment elevation
myocardial infarction treated very early and predominantly with
percutaneous coronary intervention. Heart 2004, 90(8):902–907.
29. Hanna EB, Chen AY, Roe MT: Characteristics and in-hospital outcomes of
patients with non-ST-segment elevation myocardial infarction and
chronic kidney disease undergoing percutaneous coronary intervention.
JACC Cardiovasc Interv 2011, 4(9):1002–1008.
30. Khambatta S, Farkouh ME, Wright RS, Reeder GS, McCullough PA, Smars PA,
Hickson LJ, Best PJ: Chronic kidney disease as a risk factor for acute
coronary syndromes in patients presenting to the emergency room with
chest pain. Transl Res 2012, 159(5):391–396.
doi:10.1186/1471-2369-15-152
Cite this article as: Udeanu et al.: Relationship between coronary artery
disease and C-reactive protein levels in NSTEMI patients with renal
dysfunction: a retrospective study. BMC Nephrology 2014 15:152.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
